Superluminal Medicines is a generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created. The company's platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/29/23 | $33,000,000 | Seed |
Gaingels Insight Partners NVIDIA RA Capital Management  | undisclosed |
| 10/17/24 | $120,000,000 | Series A |
Catalio Capital Cooley Eli Lilly and Company Gaingels Insight Partners NVentures RA Capital Management | undisclosed |
